Key result
Elevated interleukin-6 (> 12.40 ng/l) was an independent predictor of adverse outcomes in low-moderate risk troponin-negative NSTE-ACS patients (HR 3.62; 95% CI 1.69-7.75; p=0.001).
Why the study?
Does elevated IL-6 predict adverse clinical events in low-moderate risk troponin-negative NSTE-ACS patients?
Cohort (n=212)
Does elevated IL-6 predict adverse clinical events in low-moderate risk troponin-negative NSTE-ACS patients?
Elevated IL-6 is an independent predictor of adverse events at 6 months in low-moderate risk, troponin-negative NSTE-ACS patients, improving risk stratification beyond the TIMI risk score.
AIM: Risk stratification in acute coronary syndrome without ST-segment elevation (NSTE-ACS) and troponin-negative remains a challenge. We evaluated the value of interleukin-6 (IL-6) and amino-terminal pro-B-type natriuretic peptide (NT-proBNP) in the prognosis assessment of low-moderate risk NSTE-ACS and troponin-negative, and whether these biomarkers could improve the predictive performance of the established thrombolysis in myocardial infarction (TIMI) risk score. METHODS: A total of 212 low-moderate risk patients with NSTE-ACS and troponin-negative were prospectively studied. Clinical follow up at 6 months was performed for adverse endpoints. RESULTS: A total of 28 patients (13.5%) presented adverse clinical events. Those with adverse clinical events were associated with higher levels of IL-6 [8.58 (5.13-20.95) ng/l vs. 6.12 (4.16-9.14) ng/l, p = 0.043] and NT-proBNP [275.3 (108.6-548.2) ng/l vs. 126.8 (55.97-430.20) ng/l, p = 0.046]. In moderate risk group, we observed a higher event rate in patients with troponin-negative but elevated levels of IL-6 (p = 0.024). Only elevated IL-6 (> 12.40 ng/l) was an independent predictor of adverse outcomes [hazard ratios: 3.62, 95% confidence interval (CI) 1.69-7.75, p = 0.001]. The addition of IL-6 and history of ischaemic heart disease (IHD) to TIMI risk score significantly improved both the discrimination (integrated discrimination improvement, p = 0.003) and reclassification (Clinical Net reclassification improvement, p = 0.010) of the model for adverse events. CONCLUSIONS: Interleukin-6 is an independent predictor of adverse events in low-moderate risk patients with NSTE-ACS and troponin-negative. Its use identifies a higher risk population in moderate-risk patients. This provides together with history of IHD a better discrimination and reclassification beyond that achieved with clinical risk variables from TIMI risk score in these patients.
No takes yet. Share an insight, caveat, or question.
García-Salas et al. (2013) conducted a cohort in Low-moderate risk NSTE-ACS and troponin-negative (n=212). Elevated Interleukin-6 (> 12.40 ng/l) vs. Non-elevated Interleukin-6 was evaluated on Adverse clinical events (HR 3.62, 95% CI 1.69-7.75, p=0.001). Elevated interleukin-6 (> 12.40 ng/l) was an independent predictor of adverse outcomes in low-moderate risk troponin-negative NSTE-ACS patients (HR 3.62; 95% CI 1.69-7.75; p=0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: